Dysfunction of hemodialysis vascular access is the single most important contributor to the morbidity and mortality of patients on chronic hemodialysis. The outcome for even the most favored vascular access, the arteriovenous fistula (AVF), is dismal with up to 60% of AVFs never functioning, and increasing subsets of once functional AVFs eventually ceasing to do so. AVF failure largely reflects 3 processes: neointimal hyperplasia, impaired vasorelaxation and aberrant arterial remodeling, and thrombosis. This application seeks to continue the examination of the basis for AVF dysfunction and the exploration of relevant therapeutic strategies. In the completed cycle, we utilized peripheral, surgically-created rodent AVF models, demonstrating that these models recapitulate the essential features of functional human AVFs, including increased blood flow, and the critical features of failing human AVFs, including neointimal hyperplasia, thrombosis, and induction of vasculopathic genes. In these models, we demonstrate activation of proinflammatory transcription factors (NF-?B and AP-1), and the upregulation of maladaptive, vasculopathic genes (MCP-1) and adaptive, vasoprotective genes (eNOS and HO-1). Our proposed aims, resting and building on findings made in the concluded cycle, include the following.
AIM I. Hypothesis: The NOS system determines adaptation and injury in the AVF. Examination. Using the rat AVF model, this aim will examine the role of specific NOS isoforms, and whether the NOS cofactor, BH4, and superoxide anion scavenging determine the phenotype of the AVF. These studies will be complemented by strategies employing mutant mice to examine the roles of specific NOS isoforms, GTP cyclohydrolase (the BH4-synthesizing enzyme), and endogenous NOS inhibitor, asymmetric dimethylarginine (ADMA).
AIM II. Hypothesis: HO and its products protect against AVF failure. Examination:
This aim will determine whether the premature AVF failure in HO-1-/- mice involves impaired arterial blood flow and vascular reactivity, increased NF-?B and AP-1 activation, and/or tissue factor-dependent thrombosis.
This aim will determine the effects of HO products (carbon monoxide and bile pigments) on AVF pathobiology in HO-1+/+ mice, and whether these products can attenuate the premature failure of AVFs in HO-1-/- mice;the effect of HO induction in protecting the AVF will also be assessed. Finally, the potential protective effects in the AVF of HO-2, the constitutive HO isozyme, will be determined.
AIM III. Hypothesis: Mediators upstream and downstream of MCP-1 contribute to AVF failure. Examination:
This aim will examine the role of intermediates upstream of MCP-1 mRNA, namely, NF-?B and AP-1, and intermediates downstream of MCP-1 mRNA, specifically, MCP-1 protein and the MCP-1 receptor (CCR2). As our findings in the AVF suggest that MCP-1 may exert its adverse effects via RANTES (CCL5), the role of CCL5 in AVF failure will be examined using CCL5-/- mice and a CCL5 inhibitor. This application thus examines how 3 fundamentally important systems in vascular biology determine AVF success or failure, and may disclose therapeutic avenues for small molecules expected shortly from the pharmaceutical industry.
Patients with chronic kidney disease who are treated by chronic hemodialysis require a vascular access for hemodialysis. A vascular access allows blood to be removed from the patient, to be purified by the artificial kidney, and then returned to the patient. There are three types of vascular accesses and, overwhelmingly, the most preferred form of vascular access is the hemodialysis arteriovenous fistula. An arteriovenous fistula is created when an artery in one of the upper limbs is joined to a vein. The veins and arteries then undergo substantial enlargement with an accompanying marked elevation in blood flow. Such increased blood flow through the artery and vein of the vascular access allows the blood first to be removed from the patient, then purified by the artificial kidney, and then returned to the patient. However, more than half of these arteriovenous fistulas do not ever function and substantial numbers, with time, cease to work. This grant application studies the reasons why these blood vessels in the arteriovenous fistula either do not develop or do not function after initially doing so. The main mechanisms include failure of these blood vessels to develop and to enlarge, a special type of thickening of the blood vessel wall known as neointimal hyperplasia, and finally, clotting of these blood vessels. In the completed funding cycle, this application discovered that three different types of genes/proteins could determine either the success or failure of the arteriovenous fistula. We wish to further understand how success or failure of the arteriovenous fistula is determined by the three different types of genes/proteins. Such an understanding would likely lead to new ways of either preventing fistula failure or treating it when it occurs.
|Nath, Karl A (2014) Heme oxygenase-1 and acute kidney injury. Curr Opin Nephrol Hypertens 23:17-24|
|Kang, Lu; Grande, Joseph P; Farrugia, Gianrico et al. (2013) Functioning of an arteriovenous fistula requires heme oxygenase-2. Am J Physiol Renal Physiol 305:F545-52|
|Kang, Lu; Yamada, Satsuki; Hernandez, Melissa C et al. (2011) Regional and systemic hemodynamic responses following the creation of a murine arteriovenous fistula. Am J Physiol Renal Physiol 301:F845-51|
|Diaz Encarnacion, Montserrat M; Warner, Gina M; Cheng, Jingfei et al. (2011) n-3 Fatty acids block TNF-*-stimulated MCP-1 expression in rat mesangial cells. Am J Physiol Renal Physiol 300:F1142-51|
|Juncos, Julio P; Grande, Joseph P; Kang, Lu et al. (2011) MCP-1 contributes to arteriovenous fistula failure. J Am Soc Nephrol 22:43-8|
|Nath, Karl A; Grande, Joseph P; Kang, Lu et al. (2010) ýý-Catenin is markedly induced in a murine model of an arteriovenous fistula: the effect of metalloproteinase inhibition. Am J Physiol Renal Physiol 299:F1270-7|
|Croatt, Anthony J; Grande, Joseph P; Hernandez, Melissa C et al. (2010) Characterization of a model of an arteriovenous fistula in the rat: the effect of L-NAME. Am J Pathol 176:2530-41|
|Katusic, Zvonimir S; d'Uscio, Livius V; Nath, Karl A (2009) Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 30:48-54|
|Juncos, J P; Tracz, M J; Croatt, A J et al. (2008) Genetic deficiency of heme oxygenase-1 impairs functionality and form of an arteriovenous fistula in the mouse. Kidney Int 74:47-51|
|Tracz, Michal J; Juncos, Julio P; Grande, Joseph P et al. (2008) Induction of heme oxygenase-1 is a beneficial response in a murine model of venous thrombosis. Am J Pathol 173:1882-90|
Showing the most recent 10 out of 15 publications